ArticleCell2025
MT-125 inhibits non-muscle myosin IIA and IIB and prolongs survival in glioblastoma.
2 registry-linked trialsAbstract read
In one paragraph
Article in Cell, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 13 papers.
0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
NCT07185880 phase1 / phase2recruitingnot on this mapstarted 2026, after this paper: background citation
A Phase 1/2 Single-Arm Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of MT-125 Monotherapy With Radiation in Newly Diagnosed Glioblastoma
NCT07604285 phase1 / phase2not yet recruitingnot on this mapstarted 2026, after this paper: background citation
A Phase 1/2 Dose Escalation and Randomized Expansion Study of Safety, Tolerability, and Pharmacokinetics of MT-125 Monotherapy With Chemoradiation in Patients With Newly Diagnosed MGMT Methylated Glioblastoma
Who cites it
13 citing papers in PubMed.
- CRISPRa-identified transcription factors reprogram glioblastoma into dendritic cell-like cells to elicit systemic antitumor immunity.Cell reports. Medicine · 2026Article
- Paclitaxel induces NM2-dependent cellular contraction through GEF-H1 dissociation from microtubules and RhoA/ROCK activation in cancer cells.Molecular oncology · 2026Article
- A multi-level charged micelle-based microneedle transdermal system for immunosuppressive tumor microenvironment regulation and synergistic therapy.Materials today. Bio · 2026Article
- Amoeboid cancer cells at a glance.Journal of cell science · 2026Review
- Targeting WTAP/ROR1/WNT5A-Mediated Crosstalk Between Glioma Stem Cells and Macrophages to Normalize Tumor Vasculature and Enhance Chemotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- A song of heads and tails: myosin II conformational regulation and filament dynamics shape force generation in non-muscle cells.Biophysical reviews · 2026Review
- Research progress on the function of non-muscle myosin II during cell division.Frontiers in cell and developmental biology · 2026Review
- ECE1c promotes glioblastoma invasion via the ROCK2-MYH10 axis and interaction with ACTB.American journal of translational research · 2026Article
- Mechanical Signaling: Molecular Mechanisms, Biological Functions, Diseases, and Therapeutic Targets.MedComm · 2025Review
- Non-muscle myosin II is a promising therapeutic target.Trends in pharmacological sciences · 2025Article
- Role of nuclear ATPases in nuclear mechanics and cell migration through confined spaces: opposite effects of BRG1 and cohesin.bioRxiv : the preprint server for biology · 2025Article
- Article
- A mechanokinetic actomyosin model predicts different orthophosphate sensitivities of force and ATP turnover rate during isometric muscle contraction.Frontiers in physiology · 2025Article
Corrections and comments
- Update of
Authors and funding
18 authors.
Rajappa S KenchappaDepartment of Cancer Biology, Mayo Clinic, Jacksonville, FL 32224, USA; Department of Neurosurgery, Mayo Clinic, Jacksonville, FL 32224, USA. Electronic address: kenchappa.rajappa@mayo.edu.
Laszlo RadnaiDepartment of Molecular Medicine, The Scripps Research Institute and The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology, Jupiter, FL 33458, USA; Department of Neuroscience, The Scripps Research Institute and The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology, Jupiter, FL 33458, USA.
Erica J YoungDepartment of Molecular Medicine, The Scripps Research Institute and The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology, Jupiter, FL 33458, USA; Department of Neuroscience, The Scripps Research Institute and The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology, Jupiter, FL 33458, USA.
Natanael ZarcoDepartment of Cancer Biology, Mayo Clinic, Jacksonville, FL 32224, USA.
Li LinDepartment of Molecular Medicine, The Scripps Research Institute and The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology, Jupiter, FL 33458, USA.
Athanassios DovasDepartment of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY 10032, USA.
Christian T MeyerDepartment of Chemical and Biological Engineering, University of Colorado, Boulder, Boulder, CO 80303, USA.
Ashley HaddockDepartment of Cancer Biology, Mayo Clinic, Jacksonville, FL 32224, USA.
Alice HallDepartment of Molecular Medicine, The Scripps Research Institute and The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology, Jupiter, FL 33458, USA; Department of Neuroscience, The Scripps Research Institute and The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology, Jupiter, FL 33458, USA.
Katalin TothDepartment of Molecular Medicine, The Scripps Research Institute and The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology, Jupiter, FL 33458, USA.
Peter CanollDepartment of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY 10032, USA.
Naveen K H NagaiahDepartment of Cancer Biology, Mayo Clinic, Jacksonville, FL 32224, USA.
Gavin RumbaughDepartment of Neuroscience, The Scripps Research Institute and The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology, Jupiter, FL 33458, USA.
Michael D CameronDepartment of Molecular Medicine, The Scripps Research Institute and The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology, Jupiter, FL 33458, USA.
Theodore M KameneckaDepartment of Molecular Medicine, The Scripps Research Institute and The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology, Jupiter, FL 33458, USA.
Patrick R GriffinDepartment of Molecular Medicine, The Scripps Research Institute and The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology, Jupiter, FL 33458, USA.
Courtney A MillerDepartment of Molecular Medicine, The Scripps Research Institute and The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology, Jupiter, FL 33458, USA; Department of Neuroscience, The Scripps Research Institute and The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology, Jupiter, FL 33458, USA. Electronic address: cmiller@scripps.edu.
Steven S RosenfeldDepartment of Cancer Biology, Mayo Clinic, Jacksonville, FL 32224, USA; Department of Neurosurgery, Mayo Clinic, Jacksonville, FL 32224, USA. Electronic address: rosenfeld.steven@mayo.edu.
Funding
Zevalin Radioimmunotherapy Using a Modified TreatmentM01RR000032 · NCRR · UNIVERSITY OF SOUTHERN CALIFORNIA · PI RICH, ROBERT R. · 1985 to 2008
$23.6MViral and molecular chemotherapy of malignant CNS tumorsP50CA097247 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI GILLESPIE, G. YANCEY · 2002 to 2009
$13.5MTargeting Kif11 to Treat Glioblastoma Invasion and ProliferationR01NS073610 · NINDS · MAYO CLINIC JACKSONVILLE · PI CANOLL, PETER, ELMQUIST, WILLIAM · 2012 to 2021
$4.3MLangworthy Diversity Supplement: Image-based models of tumor-immune dynamics in glioblastomaU01CA250481 · NCI · MAYO CLINIC ARIZONA · PI CANOLL, PETER, HU, LELAND · 2021 to 2025
$3.8MMyosin II regulation of actin dynamics and the selective vulnerability of methamphetamine- and opioid-associated memoryR01DA049544 · NIDA · UNIVERSITY OF FLORIDA · PI MILLER, COURTNEY A, RUMBAUGH, GAVIN R · 2020 to 2024
$3.6MTargeting Go and Grow in GlioblastomaR01NS118513 · NINDS · MAYO CLINIC JACKSONVILLE · PI CANOLL, PETER, KENCHAPPA, RAJAPPA · 2020 to 2024
$2.8MMechanisms of Processivity in Molecular MotorsR01AR048565 · NIAMS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI ROSENFELD, STEVEN S · 2004 to 2008
$2.2MDeveloping nonmuscle II inhibitors for substance use relapseUH3NS096833 · NINDS · SCRIPPS FLORIDA · PI GRIFFIN, PATRICK ROBERT, KAMENECKA, THEODORE M · 2017 to 2020
$1.8MGenerating Synthetic Lethality in Glioblastoma with a First-In-Class Non-Muscle Myosin II InhibitorR01CA295558 · NCI · MAYO CLINIC JACKSONVILLE · PI Peter Canoll, STEVEN S ROSENFELD · 2025 to 2026
$1.2MDeveloping nonmuscle myosin II inhibitors for the treatment of glioblastomaR33NS119714 · NINDS · UNIVERSITY OF FLORIDA · PI MILLER, COURTNEY A, ROSENFELD, STEVEN S · 2022 to 2023
$964kDeveloping nonmuscle myosin II inhibitors for the treatment of glioblastomaR61NS119714 · NINDS · SCRIPPS FLORIDA · PI MILLER, COURTNEY A, ROSENFELD, STEVEN S · 2021 to 2021
$352kThe electrophysiology of biofilm development and drug resistanceK99AI175656 · NIAID · UNIVERSITY OF COLORADO · PI MEYER, CHRISTIAN T · 2023 to 2024
$277kNCI NIH HHS P50 CA097247NCI NIH HHS R01 CA295558NCI NIH HHS U01 CA250481NCRR NIH HHS M01 RR000032NIAID NIH HHS K99 AI175656NIAMS NIH HHS R01 AR048565NIDA NIH HHS R01 DA049544NINDS NIH HHS R01 NS073610NINDS NIH HHS R01 NS118513NINDS NIH HHS R33 NS119714NINDS NIH HHS R61 NS119714NINDS NIH HHS UH3 NS096833
Abstract
Glioblastoma (GBM) is the most lethal of primary brain tumors. Here, we report our studies of MT-125, a small-molecule inhibitor of non-muscle myosin II. MT-125 has high brain penetrance and an excellent safety profile, blocks GBM invasion and cytokinesis, and prolongs survival in murine GBM models. By impairing mitochondrial fission, MT-125 increases redox stress and consequent DNA damage, and it synergizes with radiotherapy. MT-125 also induces oncogene addiction to PDGFR signaling through a mechanism that is driven by redox stress, and it synergizes with FDA-approved PDGFR and mTOR inhibitors in vitro. Consistent with this, we find that combining MT-125 with sunitinib, a PDGFR inhibitor, or paxalisib, a combined phosphatidylinositol 3-kinase (PI3K)/mTOR inhibitor, significantly improves survival in orthotopic GBM models over either drug alone. Our results demonstrate that MT-125 is a first-in-class therapeutic that has strong clinical potential for the treatment of GBM.
Indexed as
Antineoplastic AgentsBrain NeoplasmsGlioblastomaNonmuscle Myosin Type IIANonmuscle Myosin Type IIBAnimalsCell Line, TumorFemaleHumansMiceSignal TransductionSunitinibAntineoplastic AgentsNonmuscle Myosin Type IIANonmuscle Myosin Type IIBSunitinibcancerglioblastomanon-muscle myosin IIoncogenic kinasesreactive oxygen speciessmall-molecule inhibitorsynergytargeted therapytoxicology
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT07185880ClinicalTrials.gov
NCT07604285ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.